Physician profile
Mark G Murray
NPI 1669594974
$40,962.70
in general payments reported to CMS, 2019-2025
30 companies · $1,328 in 2025
The $1,328 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $6,834 · 2021: $7,913 · 2022: $4,891 · 2023: $5,622 · 2024: $1,083 · 2025: $1,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,875 · Food and Beverage: $2,973 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,875.00 |
| Food and Beverage | $2,973.49 |
| Education | $183.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $35,707.69 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,022.62 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $631.25 | 2019-2025 | Xolair |
| Amgen INC. | $509.30 | 2021-2025 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $464.46 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $442.56 | 2019-2025 | |
| Kaleo, INC. | $381.20 | 2019-2023 | Auvi-Q |
| Pfizer INC. | $305.48 | 2020-2025 | |
| Csl Behring | $247.70 | 2019-2025 | Hizentra, Haegarda |
| Novartis Pharmaceuticals Corporation | $211.68 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $185.53 | 2020-2021 | |
| Lilly USA, LLC | $145.43 | 2022-2025 | Ebglyss |
| Grifols USA, LLC | $123.91 | 2022-2024 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $93.40 | 2022-2025 | Hyqvia, Takhzyro, Cuvitru |
| Biocryst US Sales Co., LLC | $62.61 | 2022-2025 | Orladeyo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $50.86 | 2022 | |
| Galderma Laboratories, L.P. | $49.34 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.75 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $36.08 | 2023 | |
| Leo Pharma INC. | $34.68 | 2023-2024 | Adbry |
| Sanofi-Aventis U.S. LLC | $34.25 | 2021-2022 | |
| Optinose US, INC. | $33.36 | 2019-2021 | |
| Organon LLC | $32.50 | 2025 | |
| Arcutis Biotherapeutics, INC. | $22.08 | 2025 | Zoryve |
| Ars Pharmaceuticals Operations, INC. | $19.89 | 2025 | Neffy |
| Dermavant Sciences, INC. | $19.34 | 2024 | Vtama |
| Ironwood Pharmaceuticals, INC | $17.61 | 2020 | |
| Octapharma USA, INC. | $15.95 | 2025 | Cutaquig |
| Incyte Corporation | $14.08 | 2025 | Opzelura |
| Biocryst Pharmaceuticals, INC. | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.